Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. reported a net loss of $162.3 million for the fiscal year ended December 31, 2025, compared to a net loss of $84.9 million in the prior year. Total revenues were $2.0 million, a significant decrease from $6.2 million in 2024, primarily due to reduced reimbursable costs from license agreements. Operating expenses increased to $180.0 million from $108.1 million, driven by a $62.5 million rise in research and development costs for clinical trials of claseprubart and the DNTH212 program, and a $9.3 million increase in general and administrative expenses. The company ended the year with $514.4 million in cash, cash equivalents, and investments, which it believes is sufficient to fund operations into 2028.

Key Takeaways